This year the meeting of the
American Society of Hematology, or ASH, in Orlando, Florida, was
very encouraging for people who are concerned about multiple myeloma. We wanted to get a wrap-up and find out what’s
significant for patients. It’s all next
on Patient Power.
Hello and welcome to Patient
Power. I’m Andrew Schorr. This program is supported through a grant
from Onyx Pharmaceuticals.
Well, I spent several days in Orlando, Florida, at the
American Society of Hematology meeting, and there was a lot of news that was very
encouraging for people who are concerned about myeloma. And whatever stage you are with the illness
or if it’s a family member, there’s something to talk about, and we did on
video with several experts, and that’s all at patientpower.info/ash, but also
we wanted to gain the perspective of another expert who we’ve invited for this
recording and also to have a little time to think about it. You know, when you step away from it where
there are so many poster sessions and so much research it can be just dizzying,
if you will. And fortunately the pace of
myeloma research and the options available seem to go increasing, so that’s
what we’ll be discussing, also answering some of the questions that have been
sent in to Patient Power.
Helping me with all this is
someone who has been living with myeloma for 16 years. Joining us from San
Jose, California, is
Jack Aiello. Jack, I know we got your
perspective on video, but you’ve had a couple of weeks to think about it. Are you encouraged in what you’ve been saying
to other patients around the country and around the world?
Yes. Thanks for inviting me, Andrew, on this call.
I really enjoyed attending ASH, and when I talk with other patients, as I did
this weekend through our support group, we’re all overwhelmed by again the
number of newer treatments available, combination treatments, new drugs,
discussions of maintenance, etc., so I’m looking forward to learning on this
conference call as well as asking questions.